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ABSTRACT 
BACKGROUND:  Thionamide antithyroid drugs (ATDs) have certain disadvantages 
and are associated with some adverse events (AEs). To overcome the problems associated 
with ATDs, a compound antithyroid ointment (CATO) containing methimazole (MMI) 
and hydrocortisone has been developed for use as a localthyroid treatment (LTT). 
OBJECT IVE:  The aim of this study was to assess the clinical effectiveness and 
tolerability of CATO LTT in patients with Graves disease (GD). 
METHODS:  This was a prospective, randomized, open-label, parallel-group clinical 
trial conducted at the Provincial Hospital Affiliated to Shandong University (Jinan, 
China). Patients with GD aged 19 to 65 years were randomized toreceive ither CATO 
LTT 0.3 g/d or oral MMI 37.5 mg/d (control group) treatment for 18 months, with 
a 4-year follow-up period. Hyperthyroid symptoms, thyroid function, granulocyte 
count, liver function, and AEs were assessed at baseline and every 2 weeks until serum 
thyroid hormone (TH) concentration normalized, at which point patients were 
assessed monthly. The primary efficacy end points were the duration of treatment 
required for serum TH concentration to normalize and the remission rate after com- 
pleting the 18-month treatment regimen. 
RESULTS:  A total of 154 patients (133 women, 21 men; mean [SD] age, 
39.6 [11.8] years; all Han Chinese) participated in the study; all patients completed 
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the 18-month treatment period. Compared with the MMI group (n 76), the CATO- 
treated group (n 78) had a significantly shorter median (range) time to restoration 
of normal serum thyroid hormone concentration (43 [12 150] vs 22 [7 60] days; 
P < 0.001), a significantly lower rate of recurrence of hyperthyroidism (309/1520 
[20.3%] vs 193/1368 [14.1%] person-time; P < 0.001), a significantly lower drug 
hypothyroidism rate (185/1520 [12.2%] vs 54/1368 [3.9%] person-time; P < 0.001), 
and a higher remission rate (year 1:46/69 [66.7%] vs 65/72 [90.3%] patients, P
0.001; year 2:40/69 [58.0%] vs 60/72 [83.3%] patients, P 0.001; year 3:34/69 
[49.3%] vs 57/72 [79.2%] patients, P < 0.001; and year 4:30/69 [43.5%] vs 55/72 
[76.4%] patients, P < 0.001). Systemic AEs occurred in 6 patients (7.9%) in the 
MMI group (drug neutropenia, 2 patients [2.6%]; epistaxis, 1 [1.3%]; hepatopathy, 
1 [1.3%]; and other systemic AEs, 2 [2.6%]), while no systemic AEs were observed/ 
reported in the CATO group. 
CONCLUSION:  This study suggests that CATO LTT was well tolerated and more 
effective than oral MMI treatment in controlling thyrotoxicosis and promoting remis- 
sion of GD in these Han Chinese patients. (Cuff Thef Res CIin Exp, 2008;69:305 
317) © 2008 Excerpta Medica Inc. 
KEY WORDS:  hyperthyroidism, treatment, antithyroid rugs, transdermal dmin- 
istration, ointment. 
INTRODUCTION 
Because the administration of thionamide antithyroid rugs (ATDs) is simple and the 
drugs are well-tolerated and efficacious, 1 2 this treatment has been widely used as a 
primary treatment for hyperthyroidism. However, ATDs have some disadvantages. 
Although study findings of ATD treatment vary greatly, it is generally agreed that the 
time to onset of action in relieving the symptoms of thyrotoxicosis and the time to 
normalize serum thyroid hormone (TH) concentration are usually 1 to 3 and 6 to 
8 weeks, respectively3,4; the hyperthyroidism remission rates with Graves disease 
(GD) are -50% (range, 30% 70%)5; and the rate of systemic adverse events (AEs) is 
-1% 5% 6 (range, 1% 15%7). Several studies 8 l0 have found that the frequency of 
hypothyroidism induced by moderate doses of ATD (methimazole [MMI] 20 
30 mg/d, carbimazole 40 mg/d, or propylthiouracil [PTU] 400 mg/d) ranged from 
28% to 70% in the initial control stage of treatment. Also, ATD is not administered 
to patients who cannot ake oral medication. These limitations make ATD inappro- 
priate for many patients with hyperthyroidism. 
Compound antithyroid ointment (CATO) was developed for transdermal dmin- 
istration. In addition to ointment bases, CATO contains 2 active ingredients 
12% MMI and 0.6% hydrocortisone (HC). 
MMI, HC, and CATO are all associated with AEs. MMI has been associated with 
systemic AEs, including agranulocytosis, granulopathy, epistaxis, hepatopathy, gas- 
trointestinal reactions, baldness, purpura, edema, and arthralgia. 6 Among the AEs 
associated with HC are hyperglycemia, hypertension, infection, iatrogenic osteoporo- 
sis, hypercortisolism, and hormone dependence, ll Patients treated with CATO may 
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develop drug hypothyroidism and topical reactions, including paresthesia (eg, sensa- 
tions of burning or dryness, pruritus, twinges), dermatitis (eg, flushing, erythema, 
desquamation, miliaria), and infection (eg, folliculitis, furundes). 
Two preclinical studies and a pilot clinical trial found that local thyroid treatment 
(LTT) with CATO was effective and well tolerated.12 14 The aim of this clinical study 
was to assess CATO LTT in patients with GD. 
PAT IENTS AND METHODS 
STUDY DES IGN 
This prospective, randomized, open-label, parallel-group clinical trial was carried 
out at Provincial Hospital Affiliated to Shandong University (Jinan, China). The 
study protocol was approved by the hospital's ethics committee. Previous studies 15,16 
indicated that the suitable duration of treatment for GD was 18 months, that most 
relapses occurred within 2 years after discontinuation of treatment, and that MMI was 
preferable treatment to PTU. Therefore, the duration of this study was 18 months 
with a 4-year follow-up period, and MMI was used as the positive control. 
PAT IENT SELECT ION 
The participants were screened from among outpatients treated at the hospital's 
Division of Endocrinology. Special observers, who were not blinded to treatment, were 
responsible for patient examination, registration, record, and distribution of the study 
treatment. Patients were enrolled between August 1, 1994, and February 1, 1995, 
and were treated for 18 months, followed by a 4-year follow-up period that ended on 
August 1, 2000. 
Patients aged 19 to 65 years with newly diagnosed, untreated GD were eligible for 
the study. The diagnosis was determined clinically and biochemically using Durman's 
criteria. 3 Patients were excluded from the study if they required radioiodine treat- 
ment, had severe complications of hyperthyroidism, or had concomitant disease (eg, 
critical or precritical hyperthyroidism, hyperthyroid cardiopathy with heart failure, 
serious hyperthyroid periodic paralysis, hyperthyroid hyperemesis, obvious abnormal 
hepatic function, granulocytopenia, infection, cardiovascular apoplexy, malignant 
tumor, serious malnutrition, pain, psychopathology, anergy). Pregnant or breast- 
feeding women were also excluded, as were patients who required any type of surgery. 
~-receptor blocking drugs and other drugs that affect TH production were not 
allowed during the study. 
Patients who met the inclusion criteria were randomized using a random number 
permutation table 17 in a 1:1 ratio to receive CATO LTT or oral MMI (control group). 
All eligible patients provided written informed consent prior to participation. 
EFFECT IVENESS ASSESSMENT 
Serum TH concentration, including total triiodothyronine (TT3), total thyroxine 
(TT4) , free triiodothyronine (FT3) , and free thyroxine (FT4) , and serum thyrotropin 
concentration were measured at baseline and every 2 weeks until the serum TH con- 
centration ormalized, at which point the interval was increased to monthly through- 
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out the remainder of the treatment period and then yearly during the follow-up 
period. At the same time, patients were assessed for signs of hyperthyroidism and they 
were asked about their symptoms. Patient hyroid size was graded based on the World 
Health Organization's methodology, is 
Serum TH and thyrotropin concentrations were measured in the hospital's nuclear 
medicine department. TT3, TT4, FT3, FT4, and thyrotropin were measured using a 
standard radioimmunoassay kit (Chinese Sciences Academy of Atomic Energy, 
Beijing, China). The normal reference ranges and the intra- and interassay CVs were 
as follows: TT3, 1.4 to 3.4 nmol/L (0.9 2.2 ng/mL), 5.3% to 8.4% and 6.7% to 9.4% 
at concentrations of 1.36 to 8.14 nmol/L; TT4, 54 to 174 nmol/L (42 135 ng/mL), 
3.6% to 6.7% and 5.6% to 12.0% at 33.2 to 207 nmol/L; FT3, 3.09 to 9.83 pmol/L 
(4.75 15.10 pg/mL), 5.6% to 7.0% at 2.20 to 37.63 pmol/dL (intraassay), and 7.2% 
to 12.4% at 1.86 to 25.16 pmol/dL (interassay); FT4, 8.07 to 26.27 pmol/L 
(10.39 33.81 pg/mL), 4.7% to 8.8% at 1.29 to 35 pmol/L (intraassay), and 7.1% to 
12.21% at 0.41 to 31.5 pmol/L (interassay); thyrotropin, 0.3 to 4.4 mlU/L, 6.7% to 
8.7% (intraassay), and 7.4% to 10.9% (interassay). Bone mineral density was surveyed 
every 6 months using dual energy x-ray absorptiometry (XR-36, Norland Co., Fort 
Atkinson, Wisconsin). To reduce bias, changes in the signs and symptoms of thyro- 
toxicosis were assessed by 2 observers (national monitors) who were not study 
investigators. 
The primary efficacy end points were the duration of treatment required for serum 
TH concentration to normalize and the remission rate after completing the 18-month 
treatment regimen. The secondary end points were the duration of treatment required 
for the signs and symptoms of thyrotoxicity to resolve and the frequency of recurrence 
of hyperthyroidism. 
TOLERABIL ITY  ASSESSMENT 
Tolerability was assessed using fasting blood samples, physical examination, and by 
querying the patients about their symptoms at baseline and every 2 weeks until serum 
TH concentration normalized, at which point the interval was increased to monthly. 
Blood was assessed using standard laboratory studies for hematology (complete blood 
count) and biochemistry (glucose concentration and liver function). An oral glucose 
tolerance test was performed at baseline and every 3 months thereafter. These tests 
were done at the hospital aboratory. AEs determined to be unrelated to treatment 
were recorded and treated. 
STUDY DRUGS 
Using LTT, 0.1 g of CATO (containing MMI 12 mg and HC 0.6 mg) was applied 
to the skin over the thyroid at the front of the neck and then rubbed and kneaded for 1 to 
3 minutes until the ointment disappeared. The dosage of CATO used in the study was 
determined based on the findings of 2 preclinical studies and a pilot clinical trial.12 14 
MMI at an initial dosage of 30 to 40 mg/d was found to be appropriate. 19In this 
study, the dosages of oral MMI were 37.5 mg/d (7.5 tablets/d; each tablet, 5 mg) and 
36 mg/d MMI contained in CATO. Patients began treatment with CATO 0.3 g/d or 
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oral MMI 37.5 mg/d in 3 divided doses (in the morning, afternoon, and evening) until 
the serum TH concentration normalized. The dose was then gradually tapered based 
on the patient's condition and serum TH concentration to a maintenance dose admin- 
istered once daily (just before going to sleep at night) to maintain a normal serum TH 
concentration. 
STAT IST ICAL  ANALYS IS  
Statistical analyses were conducted using SPSS version 10.0 (SPSS Inc., Chicago, 
Illinois). Normally distributed ata were presented as mean (SD). Data were compared 
using 2-tailed independent-sample t t sts. The median (range) for abnormally distrib- 
uted data were compared using 2 related samples with the nonparametric Wilcoxon 
signed rank test. The percentage of men versus women, thyroid size, frequencies of 
recurrence of hyperthyroidism and occurrence of drug hypothyroidism, remission rate, 
and incidences of neutropenia, epistaxis, hepatopathy, and other AEs were tested using 
a Z 2 test. All enumeration variables of 2 x 2 tables were compared using the Z 2 test; 
if a cell contained zero, the Fisher exact test was used. The remission rates in the 
2 groups after the completion of drug treatment were compared using an intent-to- 
treat analysis (ITT) 4 times (once annually) during the follow-up period. P < 0.05 was 
considered statistically significant. 
RESULTS 
A total of 162 patients were screened; 8 (4.9%) did not meet the study criteria and 
were excluded from the study. Therefore, 154 patients (133 women, 21 men; mean 
[SD] age, 39.6 [11.8] years; all Han Chinese) participated in the study; all patients 
completed the 18-month treatment period. There were no significant differences in 
demographic or clinical characteristics between the CATO group and the MMI group 
at baseline (Table I). 
The compliance rates were not significantly difterent in the CATO and MMI 
groups (93.6% [73/78] vs 96.1% [73/76] patients). The number of patients at the 
end of the 4-year follow-up period was not significantly different in the 2 groups 
(72 [92.3%] vs 69 [90.8%] patients) (Figure). The number of patients who were lost 
during follow-up was similar in the 2 groups (6 [7.7%] vs 7 [9.2%] patients). The 
reasons for withdrawal were lack of compliance (5 patients), withdrawal of consent (2), 
nonthyroidal il ness (myocardial infarction, 1; cancer, 2), and change of residence (3). 
The CATO and MMI groups diftered significantly in median (range) duration of treat- 
ment required to relieve the symptoms ofthyrotoxicosis (5 [2 30 ] vs 24 [4 108] days, 
respectively; P < 0.001), duration of treatment required for complete resolution of 
symptoms (23 [3 68] vs 60 [19 198] days; P < 0.001), and duration of treatment 
required for normalization of serum TH concentration (22 [7 60] vs 43 [ 12 150] days; 
P < 0.001). The frequency of recurrence of hyperthyroidism was significantly lower 
in the CATO group compared with the MMI group (193/1368 [14.1%] vs 309/1520 
[20.3%] person-time; P < 0.001). The remission rates were significantly higher in the 
CATO compared with the MMI group each year during the 4-year follow-up period 
(year 1: 90.3% [65/72] vs 66.7% [46/69] patients, P 0.001; year 2: 83.3% [60/72] vs 
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Random ly divided 
into 2 groups 
Withdrawal 
and 
loss to 
follow-up 
Screening (N = 154) 
1/ 
CATO-treated group I/ MMI-treated group 
(n = 78) ][  (n = 76) 
All patients completed treatment 
I r 
End of follow-up I / End of follow-up 
(n = 72) J / (n = 69) 
6-Month 
Recruitment period 
(Aug. 1, 1994- 
Feb. 1, 1995) 
18-Month 
Treatment period 
(Aug. 1, 1994- 
Aug. 1, 1996) 
4-Year 
Follow-up period 
(Feb. 1, 1996- 
Aug. 1, 2000) 
Figure. Disposition of study subjects. CATO = compound antithyroid ointment; MMI  = 
methimazole. 
58.0% [40/69], P 0.001; year 3, 79.2% [57/72] vs 49.3% D4/69], P < 0.001; 
year 4, 76.4% [55/72] vs 43.5% [30/69], P < 0.001) by ITT analysis. The frequency 
of drug hypothyroidism was significantly lower in the CATO group than in the MMI 
group (3.9% [54/1368 ] vs 12.2% [185/1520] person-time; P < 0.001) (Table TT). 
Systemic AEs occurred in 6 patients (7.9%) in the MMI group (drug neutropenia, 
2 patients [2.6%]; epistaxis, 1 [1.3%]; hepatopathy, 1 [1.3%]; and other systemic 
AEs, 2 [2.6%]), while no systemic AEs were observed/reported in the CATO group. 
The systemic AE rates were not significantly different between the 2 groups (Fisher 
exact test) (Table TT). No HC-related systemic AEs were observed/reported in the 
CATO-treated group. 
In the CATO group, 4 of 78 patients (5.1%) experienced topical skin reactions, 
3 (3.8%) had paresthesia, nd 1 (1.3%) had dermatitis medicamentosa; no patient in 
the MMI group reported any local AEs. There was no significant between-group dif- 
ference in the occurrence rate of the local AEs. The AEs were resolved by adjusting 
the application method (eg, discontinuing washing with soap, ventilating the neck, 
and temporarily reducing the frequencies ofdrug administration) or by adding a topical 
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drug (eg, mucopolysaccharide polysulfate or glucocorticoid cream), which did not 
affect CATO treatment. 
DISCUSSION 
Three factors the shallow location of the thyroid gland in the subcutaneous ti sue, goi- 
ter, and accelerated transthyroid blood and lymph circulation during hyperthyro id is~ 
might help a hyperfunctioning thyroid gland absorb topical medication. Use of a 
transdermal treatment system on the skin over the thyroid gland should not only 
promote accumulation of active ingredients in the thyroid, to increase ffectiveness, 
but should also decrease the amount of the drug that enters the circulatory system, 
possibly reducing systemic AEs. MMI has been found to have chemical properties that 
allow it to be rapidly absorbed through the skin. 4,2° 23 Some studies in felines 24 27 
have found transdermal MMI to be effective and well tolerated in treating cats with 
hyperthyroidism. Experimental pharmacokinetic studies 22,23 found that MMI LTT 
increased the drug concentration i  the thyroid and decreased the serum drug concen- 
tration. However, the minimal efficacy of MMI monotherapy in the treatment of 
hyperthyroidism has been improved by the addition of topical glucocorticoids. 14 
Glucocorticoids have multiple-level and successive inhibitions on thyroid hormone 
synthesis, secretion, and activation and a synergistic action with MMI. 28 30 Glu- 
cocorticoids plus ATD were found to be effective in the treatment of thyroid cri- 
sis 3'31'32 and amiodarone-induced thyrotoxicosis, 29,33 36 in rapid preoperative prepara- 
tion for thyroidectomy, 3° 37,38 in thyrotoxicosis resistant o ATD, 39 and in reducing 
goiter size. 4° Intrathyroidal injection of low-dosage glucocorticoids combined with 
oral ATD also achieved a synergistic effect with no evident systemic AEs in GD. 41 43 
However, due to the systemic disadvantages of high-dosage glucocorticoids and the 
drawbacks of injection, these therapies have not been widely used as long-term anti- 
thyroid treatment. The precise mechanism of action of glucocorticoids in hyperthy- 
roidism remains unknown. Ointment was chosen as the vehicle for applying MMI and 
HC because of its acceptability to patients, its convenience for long-term application, 
and its distribution and penetrating properties (especially when a penetration enhancer 
is added). 
Due to insufficient data concerning CATO LTT, another clinical trial 14 was con- 
ducted based on a previous preclinical study and a pilot clinical trial. 13 Forty-eight pa- 
tients with matched clinical features, who had new or recurrent untreated hyper- 
thyroidism, were assigned to 4 groups of 12 patients each. They underwent LTT with 
ointment at 1 of 3 concentrations or ointment applied to the retroauricular skin 
(an area where drugs penetrate the skin easily) for 2 months. In the group treated with 
24% MMI/1.2% HC ointment (high concentration), the time required to achieve u- 
thyroidism and the number of patients who achieved it were 26.72 (8.3) days and 12/12 
(100%), respectively; in the 12% MMI/0.6% HC group (moderate concentration), 
25.4 (6.1) days and 12/12 (100%); in the 6% MMI/0.3% HC group (low concentration), 
32.7 (10.8) days and 11/12 (91.7%); and in the group treated with 12% MMI/0.6% 
HC applied to the retroauricular skin, 42.8 (14.3) days and 5/12 (41.7%). The time 
required to achieve uthyroidism was significantly shorter in the moderate-concentration 
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group than in the low-concentration group (P <0.05) and the retroauricular skin 
group (P <0.01); the time to euthyroidism was not significantly different i  the 
moderate-concentration and the high-concentration groups. Therefore, 12% MMI/0.6% 
HC was found to be preferable to the other concentrations tested and LTT was the 
better oute of administration for the treatment of thyrotoxicosis. 
The treatment group had a significant difference when compared with the control 
group, with regard to the primary and secondary end points, which might be attrib- 
uted to the synergistic action of MMI and HC. MMI or HC monotherapy was found 
to be less effective than treatment with CATO in controlling thyrotoxicosis, and HC 
was found to inhibit the thyroid gland from absorbing iodine and to block the bio- 
synthesis of intrathyroid iodine. 44 In that study, 20 patients (25.6%) in the CATO- 
treated group experienced normalization of their serum TH concentration within 
14 days, as did 98 of > 3000 thyrotoxicosis patients treated with CATO in the past 
18 years. This was shorter than the time it takes ATD to inhibit synthesis of intrathy- 
roidal TH to restore the euthyroid state (1 2 months). 3,4 Glucocorticoids have been 
reported to stabilize membranes and to promote production of enzymes that inhibit 
the proteolytic action of lysosomes on thyroglobulin. 34,45 Therefore, CATO inhibits 
the release of triiodothyronine and thyroxine from the thyroid. These findings suggest 
that CATO might inhibit the secretion of intrathyroidal TH. Moreover, glucocorti- 
coids can induce thyroid cell apoptosis. 3,46,47 
The CATO group had a more stable euthyroid state than the MMI group. This 
might have resulted from its faster therapeutic response, the greater ease of adjusting 
the dosage based on the patient's condition and serum TH concentration, and smaller 
individual differences in pharmacokinetics stemming from percutaneous absorption 
and avoidance of the metabolic processes prior to absorption by the thyroid. The GD 
remission rate was significantly higher in the CATO group than the MMI group, sug- 
gesting that CATO treatment was associated with greater immunosuppressive activity 
than MMI. Glucocorticoids might inhibit cellular and humoral immunity in the 
thyroid. 48,49 Restoration of the euthyroid state was found to be the cause of the 
ATD-induced immunomodulatory effect for GDS°; therefore, more stable euthyroid- 
ism during CATO LTT might improve the recovery of immunologic function. 
CATO LTT was not associated with any systemic AEs, except drug hypothyroid- 
ism, which occurred significantly less frequently in the CATO group than the MMI 
group. Although CATO was associated with topical AEs, the incidence was low, the 
AEs were mild and transient, and treatment was not substantially affected. 
This study may have limitations due to bias produced by the small number of 
patients and the similarity of the participants (ie, all were Han Chinese and came 
from iodine-sufficient or iodine-rich regions). Another limitation was due to the 
lack of certain assays (ie, reagents of thyroid-stimulating immunoglobulin and 
urine iodine were not available). Additional imitations were due to the open-label, 
single-center design, and the loss of some patients during follow-up. The mecha- 
nism of action of CATO LTT in hyperthyroidism is unknown and needs to be 
explored. Additional ong-term, multicenter, blinded clinical studies of CATO LTT 
in GD are needed. 
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CONCLUSION 
This study suggests that CATO LTT was well-tolerated and more effective than oral 
MMI treatment in controlling thyrotoxicosis and promoting remission of GD in these 
Han Chinese patients. 
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